Table 4. Clinical data of the human study cohort.
| Gender | Mean age | Clinical information | HD stage | CAG-1 | CAG-2 | HRR | CS activity | Disease burden |
|---|---|---|---|---|---|---|---|---|
| ♀ | 33.3±9.7 | control | all | 2x NA | ||||
| ♂ | control | all | all | |||||
| ♀ | 38.2±14.4 | HDEMC | PM | 19.8±4.1 | 44.8±3.3 | all | NA | 391 |
| ♀ | HDEMC | PM | NA | 274.5 | ||||
| ♀ | HDEMC | PM | X | 350 | ||||
| ♂ | HDEMC | PM | X | 294.5 | ||||
| ♂ | HDEMC | PM | NA | 264.5 | ||||
| ♂ | HDEMC | PM | X | 315 | ||||
| ♂ | HDEMC | PM | X | 259 |
The clinical data of the study cohort is shown according to gender, age, clinical information, Huntington’s Disease (HD) stage, CAG repeats, disease burden (= (CAGn-35.5) X age [28]), application of the sample for high-resolution respirometry (HRR) and citrate synthase (CS) activity, which was not possible to be determined for all samples, due to the small size of the biopsy, indicated by not available (NA).